All In Biotech

Drug Trial Radar · NCT06675929

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

Safety, Tolerability and Pharmacodynamics of BI 770371 Administered Intravenously in Patients With Compensated Cirrhosis Due to MASH: a Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jan 20, 2025

Primary completion

Jan 13, 2026

Study completion Jan 13, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of this study is to find out how well a medicine called BI 770371 is tolerated. Participants are put into 2 groups by chance. One group gets BI 770371 as an infusion into a vein and the other group gets placebo as an infusion into a vein. Placebo infusions look like BI 770371 infusions but do not contain any medicine. Participants get an infusion every 3 weeks for 12 weeks. Participants are in the study for about 5 months. During this time, they visit the study site 16 times. This also includes 1 overnight stay at the study site. The doctors regularly check participants' health and collect information on any health problems of the participants. The results are compared between the 2 groups.

Conditions

  • Compensated Liver Cirrhosis
  • Metabolic Dysfunction Associated Steatohepatitis (MASH)

Interventions

  • BI 770371Drug

    BI 770371

  • Placebo for BI 770371Drug

    Placebo for BI 770371

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment-emergent, drug-related adverse events in the BI 770371 and placebo armsTime frame: Up to Week 15

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • The Institute for Liver Health II dba Arizona Clinical Trials

    Chandler, Arizona

  • Southern California Research Center

    Coronado, California

  • Catalina Research Institute, LLC-Montclair-49051

    Montclair, California

  • Knowledge Research Center

    Orange, California

  • Inland Empire Clinical Trials, LLC

    Rialto, California

  • Peak Gastroenterology Associates-Colorado Springs-67762

    Colorado Springs, Colorado

  • Evolution Clinical Trials

    Miami, Florida

  • Blessed Health Care

    Miami, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • The Liver Institute at Methodist Dallas

    Dallas, Texas

  • Houston Research Institute

    Houston, Texas

  • American Research Corporation at the Texas Liver Institute

    San Antonio, Texas

  • Pinnacle Clinical Research, LLC

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.